Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma

Table 1

Key details of the patients’ diagnosis, treatment, and outcome.

	Patient 1	Patient 2	Patient 3
Age at diagnosis	2 years and 10 months	8 months	2 years
Date of diagnosis	04 June 2018	04 September 2019	18 December 2019
INSS stage	4	4	4
MYCN status	MYCN amplified	MYCN amplified	MYCN and DDX1 amplified
Primary tumor	Left adrenal gland	Left adrenal gland	Left adrenal gland
Metastases	(i) Multiple enlarged abdominal and pelvic lymph nodes; (ii) Solid CNS lesions and leptomeningeal thickening; (iii) BM involvement	(i) Enlarged para-aortic and paracaval lymph nodes; (ii) BM involvement	(i) Metastasis in mandibula; (ii) Enlarged cervical and tonsilar lymph nodes; (iii)  BM involvement
Treatment	(i)  8 cycles of COJEC; (ii) 1 cycle of DB; (iii) 2 cycles of TVD; (iv) Surgery; (v) 1 cycle of TVD; (vi) 1 cycle of DB; (vii) BuMel + ASCT; (viii) 4 cycles of DB	(i) 8 cycles of COJEC; (ii) 1 cycle of DB; (iii)  Surgery; (iv) 1 cycle of DB; (v) BuMel + ASCT	(i) 7 cycles of COJEC; (ii) 3 cycles of I/T and DB^∗; (iii) Surgery; (iv) BuMel + ASCT
Current status	Complete remission	Complete remission	Complete remission

^∗I/T was administered on days 1−5 and DB on days 6−16 of each 21-day cycle. ASCT: autologous stem cell transplant; BM: bone marrow; BuMel: busulfan and melphalan; CNS: central nervous system; COJEC: cisplatin (C), vincristine (O), carboplatin (J), etoposide (E), and cyclophosphamide (C); DB: dinutuximab beta; D: doxorubicin; INSS: International Neuroblastoma Staging System; I/T: irinotecan/temozolomide; T: topotecan; V: vincristine.